Friday, July 10, 2026

pharma · Ulcerative Colitis · Diabetes Mellitus, Type 2

Eli Lilly and

Eli Lilly and is a pharma organization headquartered in GURGAON, CN. Primary therapeutic focus areas include Ulcerative Colitis, Diabetes Mellitus, Type 2, Breast Neoplasms, Non Small Cell Lung Cancer, Systemic Lupus Ery

Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
55,860 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Lilly Corporate Center, Indianapolis, Indiana 46285, US
Employees
55,860
Programs
62
Drugs
42
Patents
0
Clinical program

Abemaciclib

Approved · small molecule · Breast Neoplasms

Abemaciclib for Breast Neoplasms is a Approved program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).

← All Eli Lilly and Company projects Approved small molecule completed

Internal code 17782

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Eli Lilly and Company
Phase
Approved
Modality
small_molecule
Indication
Breast Neoplasms
Status
completed
Trials
1